EQ-5D in Central and Eastern Europe: 2000–2015
<p>Objective: Cost per quality-adjusted life year data are required for reimbursement decisions in many Central and Eastern European (CEE) countries. EQ-5D is by far the most commonly used instrument to generate utility values in CEE. This study aims to systematically review the literature on...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Springer Verlag
2017
|
| _version_ | 1826293643151933440 |
|---|---|
| author | Rencz, F Gulácsi, L Drummond, M Golicki, D Prevolnik Rupel, V Simon, J Stolk, E Brodszky, V Baji, P Závada, J Petrova, G Rotar, A Péntek, M |
| author_facet | Rencz, F Gulácsi, L Drummond, M Golicki, D Prevolnik Rupel, V Simon, J Stolk, E Brodszky, V Baji, P Závada, J Petrova, G Rotar, A Péntek, M |
| author_sort | Rencz, F |
| collection | OXFORD |
| description | <p>Objective: Cost per quality-adjusted life year data are required for reimbursement decisions in many Central and Eastern European (CEE) countries. EQ-5D is by far the most commonly used instrument to generate utility values in CEE. This study aims to systematically review the literature on EQ-5D from eight CEE countries.</p> <p>Methods: An electronic database search was performed up to 1 July 2015 to identify original EQ-5D studies from the countries of interest. We analysed the use of EQ-5D with respect to clinical areas, methodological rigor, population norms and value sets.</p> <p>Results: We identified 143 studies providing 152 country-specific results with a total sample size of 81,619: Austria (n = 11), Bulgaria (n = 6), Czech Republic (n = 18), Hungary (n = 47), Poland (n = 51), Romania (n = 2), Slovakia (n = 3) and Slovenia (n = 14). Cardiovascular (21 %), neurologic (17 %), musculoskeletal (15 %) and endocrine, nutritional and metabolic diseases (13 %) were the most frequently studied clinical areas. Overall, 112 (78 %) of the studies reported EQ VAS results and 86 (60 %) EQ-5D index scores, of which 27 (31 %) did not specify the applied tariff. Hungary, Poland and Slovenia have population norms. Poland and Slovenia also have a national value set.</p> <p>Conclusions: Increasing use of EQ-5D is observed throughout CEE. The spread of health technology assessment activities in countries seems to be reflected in the number of EQ-5D studies. However, improvement in informed use and methodological quality of reporting is needed. In jurisdictions where no national value set is available, in order to ensure comparability we recommend to apply the most frequently used UK tariff. Regional collaboration between CEE countries should be strengthened.</p> |
| first_indexed | 2024-03-07T03:33:18Z |
| format | Journal article |
| id | oxford-uuid:bb6e64d6-e307-48d4-a20c-ee2ff08cf8d2 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T03:33:18Z |
| publishDate | 2017 |
| publisher | Springer Verlag |
| record_format | dspace |
| spelling | oxford-uuid:bb6e64d6-e307-48d4-a20c-ee2ff08cf8d22022-03-27T05:17:02ZEQ-5D in Central and Eastern Europe: 2000–2015Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:bb6e64d6-e307-48d4-a20c-ee2ff08cf8d2Symplectic Elements at OxfordSpringer Verlag2017Rencz, FGulácsi, LDrummond, MGolicki, DPrevolnik Rupel, VSimon, JStolk, EBrodszky, VBaji, PZávada, JPetrova, GRotar, APéntek, M<p>Objective: Cost per quality-adjusted life year data are required for reimbursement decisions in many Central and Eastern European (CEE) countries. EQ-5D is by far the most commonly used instrument to generate utility values in CEE. This study aims to systematically review the literature on EQ-5D from eight CEE countries.</p> <p>Methods: An electronic database search was performed up to 1 July 2015 to identify original EQ-5D studies from the countries of interest. We analysed the use of EQ-5D with respect to clinical areas, methodological rigor, population norms and value sets.</p> <p>Results: We identified 143 studies providing 152 country-specific results with a total sample size of 81,619: Austria (n = 11), Bulgaria (n = 6), Czech Republic (n = 18), Hungary (n = 47), Poland (n = 51), Romania (n = 2), Slovakia (n = 3) and Slovenia (n = 14). Cardiovascular (21 %), neurologic (17 %), musculoskeletal (15 %) and endocrine, nutritional and metabolic diseases (13 %) were the most frequently studied clinical areas. Overall, 112 (78 %) of the studies reported EQ VAS results and 86 (60 %) EQ-5D index scores, of which 27 (31 %) did not specify the applied tariff. Hungary, Poland and Slovenia have population norms. Poland and Slovenia also have a national value set.</p> <p>Conclusions: Increasing use of EQ-5D is observed throughout CEE. The spread of health technology assessment activities in countries seems to be reflected in the number of EQ-5D studies. However, improvement in informed use and methodological quality of reporting is needed. In jurisdictions where no national value set is available, in order to ensure comparability we recommend to apply the most frequently used UK tariff. Regional collaboration between CEE countries should be strengthened.</p> |
| spellingShingle | Rencz, F Gulácsi, L Drummond, M Golicki, D Prevolnik Rupel, V Simon, J Stolk, E Brodszky, V Baji, P Závada, J Petrova, G Rotar, A Péntek, M EQ-5D in Central and Eastern Europe: 2000–2015 |
| title | EQ-5D in Central and Eastern Europe: 2000–2015 |
| title_full | EQ-5D in Central and Eastern Europe: 2000–2015 |
| title_fullStr | EQ-5D in Central and Eastern Europe: 2000–2015 |
| title_full_unstemmed | EQ-5D in Central and Eastern Europe: 2000–2015 |
| title_short | EQ-5D in Central and Eastern Europe: 2000–2015 |
| title_sort | eq 5d in central and eastern europe 2000 2015 |
| work_keys_str_mv | AT renczf eq5dincentralandeasterneurope20002015 AT gulacsil eq5dincentralandeasterneurope20002015 AT drummondm eq5dincentralandeasterneurope20002015 AT golickid eq5dincentralandeasterneurope20002015 AT prevolnikrupelv eq5dincentralandeasterneurope20002015 AT simonj eq5dincentralandeasterneurope20002015 AT stolke eq5dincentralandeasterneurope20002015 AT brodszkyv eq5dincentralandeasterneurope20002015 AT bajip eq5dincentralandeasterneurope20002015 AT zavadaj eq5dincentralandeasterneurope20002015 AT petrovag eq5dincentralandeasterneurope20002015 AT rotara eq5dincentralandeasterneurope20002015 AT pentekm eq5dincentralandeasterneurope20002015 |